Tatva Chintan Pharma Stock Screener | Share Price & Fundamental Analysis

Share Price NSE
₹1194.40
▼ -48.80 (-3.93%)
2026-02-20 00:00:00
Share Price BSE
₹1195.95
▼ -44.10 (-3.56%)
2026-02-20 00:00:00
Track Tatva Chintan Pharma share price live with TickJournal's free stock screener. Analyze Tatva Chintan Pharma share price history trends and compare 52-week high low levels. Calculate TATVA stock fair value using fundamental analysis and view live share price charts. Determine Tatva Chintan Pharma share intrinsic value and compare it with current TATVA share price. Record your Tatva Chintan Pharma trades in TickJournal's free trading journal and track your portfolio performance.
EPS (TTM) ₹2.44
Dividend Yield 0.08%
Debt to Equity 0.03
TATVA 52 Week High ₹1588.70
Tatva Chintan Pharma 52 Week Low ₹637.00
Operating Margin 8.00%
Profit Margin 0.92%
EBITDA ₹10.00
Net Income ₹1.00
Total Assets ₹836.00
Total Equity ₹739.00

Tatva Chintan Pharma Share Price History - Stock Screener Chart

Screen TATVA historical share price movements with interactive charts. Analyze price trends and patterns.

Tatva Chintan Pharma Company Profile - Fundamental Screener

Screen Tatva Chintan Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for TATVA shares.
Sector Chemicals
Industry Specialty Chemicals
Sub-Sector Specialty Chemicals
Segment E
ISIN INE0GK401011

Tatva Chintan Pharma Balance Sheet Screener

Screen TATVA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023 2022 2021 2020 2019 2018
Assets
Total Assets 836 819 759 658 315 249 188 0
Current Assets 265 298 312 436 184 133 114 0
Fixed Assets 526 427 196 160 120 111 67 0
Liabilities
Total Liabilities 836 819 759 658 315 249 188 0
Current Liabilities 1 2 5 14 31 44 35 0
Non-Current Liabilities 0 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 739 737 515 473 166 118 80 0
Share Capital 23 23 22 22 20 8 8 0
Reserves & Surplus 715 714 493 451 146 110 72 0

Tatva Chintan Pharma Income Statement Screener - Profit & Revenue Analysis

Screen Tatva Chintan Pharma income statement and profit fundamentals. Analyze TATVA quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Tatva Chintan Pharma share price evaluation.
Item 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar 2022-Jun 2022-Sept
Revenue 109 118 125 133 103 107 84 86 125 115 97 85 99 90 92
Expenses 99 100 101 106 83 93 78 79 112 93 76 73 77 73 79
EBITDA 10 19 23 27 20 14 6 7 14 22 21 12 22 17 13
Operating Profit % 8.00% 15.00% 18.00% 19.00% 16.00% 12.00% 7.00% 8.00% 10.00% 19.00% 21.00% 13.00% 22.00% 17.00% 12.00%
Depreciation 7 9 9 9 6 7 7 7 3 6 7 7 2 2 2
Interest 0 0 1 1 0 0 0 0 3 3 3 0 1 1 1
Profit Before Tax 2 9 14 18 14 7 -1 0 8 13 11 5 19 14 9
Tax 1 3 4 3 4 2 0 0 -9 4 3 2 2 4 2
Net Profit 1 7 10 15 10 5 -1 0 17 10 8 4 18 10 7
EPS 0.44 2.84 4.24 6.49 4.11 2.23 -0.29 0.06 7.65 4.29 3.43 1.48 7.90 4.42 3.21

Tatva Chintan Pharma Cash Flow Screener - Liquidity Fundamentals

Screen TATVA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March
Operating Activities 25 98 28 20 20 25 7 13
Investing Activities -65 -121 -101 -197 -21 -40 -17 -30
Financing Activities 17 31 38 235 -5 10 17 7
Net Cash Flow -24 8 -36 59 -6 -5 8 -10

Tatva Chintan Pharma Shareholding Pattern Screener

See Tatva Chintan Pharma shareholding pattern with promoter, FII, and DII holdings. Check Tatva Chintan Pharma promoter holding and ownership changes for TATVA on TickJournal.
Item 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec
Promoter Holding 72.02% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02%
FII Holding 3.30% 3.26% 3.39% 4.17% 3.65% 3.37% 3.33% 3.36%
DII Holding 5.46% 5.11% 3.86% 3.33% 12.84% 10.63% 6.82% 6.34%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 16.92% 17.47% 18.29% 17.91% 10.49% 12.44% 15.95% 16.33%
Other Holding 2.30% 2.14% 2.44% 2.57% 1.00% 1.54% 1.87% 1.95%
Shareholder Count 78,393 76,792 73,331 68,657 73,730 73,912 79,623 79,009

Tatva Chintan Pharma Share Dividend Screener - Share Yield Analysis

Check Tatva Chintan Pharma dividend history with payout and yield data. View Tatva Chintan Pharma dividend details including ex-dates and amounts for TATVA stock.
Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹1.00 0.08%
2024-March ₹2.00 0.30%
2023-March ₹2.00 0.19%
2022-March ₹2.00 0.12%
2021-March ₹5.00 0.22%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Tatva Chintan Pharma Stock Index Membership

See which indices include Tatva Chintan Pharma stock. Check TATVA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.

Tatva Chintan Pharma Market Events Screener - Corporate Actions

Get Tatva Chintan Pharma corporate actions including splits, bonuses, and buybacks. Check Tatva Chintan Pharma stock events that may affect TATVA share price.
Announcement Date Record Date Event Type Information Price Impact
Dividend ₹ 1.00 /share 42.95%
Dividend ₹ 2.00 /share -10.87%
Dividend ₹ 2.00 /share -20.78%
Annual General Meeting NA -2.87%
Dividend ₹ 2.00 /share 0.06%
Annual General Meeting NA -2.06%
2026-01-21 2026-01-21 Quarterly Result Announcement NA 8.22%
2025-10-31 2025-10-31 Quarterly Result Announcement NA 5.47%
2025-07-24 2025-07-24 Quarterly Result Announcement NA 5.55%
2025-05-02 2025-05-02 Quarterly Result Announcement NA -7.28%
2025-01-28 2025-01-28 Quarterly Result Announcement NA -3.45%
2024-10-25 2024-10-25 Quarterly Result Announcement NA -5.26%

Tatva Chintan Pharma Competitors Screener - Peer Comparison

Screen TATVA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Pidilite Industries 150,550 65.78 13,388 6.91% 2,096 53.81
SRF 83,989 47.32 14,826 12.13% 1,251 44.35
Gujarat Fluorochemicals 37,327 56.70 4,853 10.61% 546 53.36
Navin Fluorine International 32,291 61.86 2,393 12.83% 289 54.10
Himadri Speciality Chemical 22,720 32.47 4,664 10.33% 555 42.68
Deepak Nitrite 22,393 42.48 8,366 7.84% 697 51.68
Atul 19,533 32.12 5,692 18.99% 499 66.72
Aarti Industries 16,186 44.67 7,285 14.16% 331 65.42
BASF 15,815 43.52 15,339 10.81% 479 43.91
Vinati Organics 15,536 35.79 2,293 18.24% 405 40.39

Tatva Chintan Pharma Company Announcements - News Screener

Screen TATVA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-02-18 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View
2026-02-16 Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011 View
2026-02-16 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 View
2026-02-16 Disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations 2011 View
2026-02-16 Filing Of Report Under Regulation 7(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations 2015 As Amended (SEBI Insider Trading Regulations) View
2026-01-29 Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011 View
2026-01-24 Announcement under Regulation 30 (LODR)-Earnings Call Transcript View
2026-01-22 Announcement under Regulation 30 (LODR)-Newspaper Publication View
2026-01-21 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome View
2026-01-21 Announcement under Regulation 30 (LODR)-Investor Presentation View
2026-01-21 Board Meeting Outcome for Board Meeting Outcome For Outcome Of The Board Meeting Held On 21.01.2026 View
2026-01-21 Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 December 2025 View
2026-01-12 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View
2026-01-12 Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday 21.01.2026 View
2026-01-08 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 View
2025-12-26 Closure of Trading Window View
2025-11-22 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View
2025-11-15 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View
2025-11-11 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View
2025-11-07 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View